BNP Paribas Financial Markets’s ADC Therapeutics ADCT Stock Holding History

BNP Paribas Financial Markets’s Portfolio ADCT Stock Details ADCT Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$699K	Sell	652,849 -207,642	-24%	-$606K	﹤0.01%	3567
2026 Q1	$3.23M	Buy	860,491 +29,588	+4%	+$117K	﹤0.01%	2349
2025 Q4	$2.93M	Buy	830,903 +142,432	+21%	+$578K	﹤0.01%	2385
2025 Q3	$2.75M	Buy	688,471 +90,679	+15%	+$286K	﹤0.01%	2392
2025 Q2	$1.6M	Sell	597,792 -94,286	-14%	-$198K	﹤0.01%	2617
2025 Q1	$976K	Sell	692,078 -24,590	-3%	-$41.8K	﹤0.01%	2805
2024 Q4	$1.43M	Buy	+716,668	New	+$1.88M	﹤0.01%	2589
2022 Q4	–	Sell	-726	Closed	-$3.5K	–	4033
2022 Q3	$3.5K	Buy	+726	New	+$5.26K	﹤0.01%	4285

Other funds holding ADCT

NCM

Nantahala Capital Management New Canaan, Connecticut $3.01B AUM 119.46% 1-Year Est. Return

Redmile Group San Francisco, California $1.49B AUM 208.7% 1-Year Est. Return

TCM

TCG Crossover Management Palo Alto, California $4.16B AUM 983.43% 1-Year Est. Return

Prosight Management Dallas, Texas $580M AUM 29.81% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Point72 Asset Management Stamford, Connecticut $90.7B AUM 77.13% 1-Year Est. Return

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

Millennium Management New York $276B AUM 44.8% 1-Year Est. Return

Citadel Advisors Miami, Florida $875B AUM 40.91% 1-Year Est. Return

Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return

BNP Paribas Financial Markets's ADCT Position: Q2 2026 in Review

BNP Paribas Financial Markets reduced its ADC Therapeutics (ADCT) stake by 24% in Q2 2026, selling an estimated $606K and leaving 652,849 shares worth $699K. The position accounts for ﹤0.01% of the portfolio, ranked #3567.

BNP Paribas Financial Markets first reported a position in ADCT in Q3 2022 and has held it in 8 quarters since. The position peaked at $3.23M in Q1 2026. 114 funds tracked by Wall St. Rank hold ADCT as of Q2 2026.

BNP Paribas Financial Markets held 652,849 shares of ADC Therapeutics worth $699K as of Q2 2026.
BNP Paribas Financial Markets sold 207,642 ADC Therapeutics shares in Q2 2026, an estimated $606K.
ADC Therapeutics made up ﹤0.01% of BNP Paribas Financial Markets's portfolio in Q2 2026, its #3567 holding.
BNP Paribas Financial Markets first reported a position in ADC Therapeutics in Q3 2022 and has held it in 8 quarters since.
BNP Paribas Financial Markets's ADC Therapeutics position peaked at $3.23M in Q1 2026.
114 funds tracked by Wall St. Rank held ADC Therapeutics as of Q2 2026.

Based on BNP Paribas Financial Markets's 13F filing for Q2 2026, filed 13 Aug 2026.